ASPEN AEROGELS INC (ASPN)
US04523Y1055 - Common Stock
Taking everything into account, ASPN scores 4 out of 10 in our fundamental rating. ASPN was compared to 84 industry peers in the Chemicals industry. ASPN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASPN shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year ASPN has reported negative net income.
ASPN had a negative operating cash flow in the past year.
ASPN had negative earnings in each of the past 5 years.
ASPN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ASPN's Return On Assets of -4.42% is on the low side compared to the rest of the industry. ASPN is outperformed by 76.19% of its industry peers.
Looking at the Return On Equity, with a value of -6.28%, ASPN is doing worse than 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.42% | ||
| ROE | -6.28% | ||
| ROIC | N/A |
ROA(3y)-13.21%
ROA(5y)-15.23%
ROE(3y)-18.92%
ROE(5y)-22.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ASPN has a Gross Margin (30.24%) which is in line with its industry peers.
In the last couple of years the Gross Margin of ASPN has grown nicely.
The Profit Margin and Operating Margin are not available for ASPN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.88%
GM growth 5Y14.41%
2. Health
2.1 Basic Checks
ASPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ASPN has been increased compared to 1 year ago.
ASPN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ASPN has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.05 indicates that ASPN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.05, ASPN belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
A Debt/Equity ratio of 0.25 indicates that ASPN is not too dependend on debt financing.
ASPN has a better Debt to Equity ratio (0.25) than 77.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.05 |
ROIC/WACCN/A
WACC8.48%
2.3 Liquidity
ASPN has a Current Ratio of 4.01. This indicates that ASPN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 4.01, ASPN belongs to the best of the industry, outperforming 88.10% of the companies in the same industry.
ASPN has a Quick Ratio of 3.29. This indicates that ASPN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.29, ASPN belongs to the best of the industry, outperforming 88.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.01 | ||
| Quick Ratio | 3.29 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 76.47% over the past year.
ASPN shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.37%.
The Revenue has been growing by 17.99% on average over the past years. This is quite good.
EPS 1Y (TTM)76.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.67%
Revenue 1Y (TTM)53.37%
Revenue growth 3Y33.51%
Revenue growth 5Y17.99%
Sales Q2Q%107.3%
3.2 Future
ASPN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.69% yearly.
Based on estimates for the next years, ASPN will show a very strong growth in Revenue. The Revenue will grow by 33.16% on average per year.
EPS Next Y111.93%
EPS Next 2Y73.6%
EPS Next 3Y55.69%
EPS Next 5Y43.69%
Revenue Next Year67.97%
Revenue Next 2Y54.47%
Revenue Next 3Y44.65%
Revenue Next 5Y33.16%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ASPN. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 44.99, ASPN can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ASPN is valued a bit more expensive than 73.81% of the companies in the same industry.
ASPN is valuated expensively when we compare the Price/Forward Earnings ratio to 19.91, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 44.99 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ASPN's earnings are expected to grow with 55.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.6%
EPS Next 3Y55.69%
5. Dividend
5.1 Amount
No dividends for ASPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASPEN AEROGELS INC
NYSE:ASPN (6/14/2024, 7:04:00 PM)
After market: 29.81 -0.29 (-0.96%)30.1
-0.57 (-1.86%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.29B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 44.99 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.42% | ||
| ROE | -6.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.24% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.01 | ||
| Quick Ratio | 3.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)76.47%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y111.93%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)53.37%
Revenue growth 3Y33.51%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y